Iovance Biotherapeutics, Inc.

280 articles about Iovance Biotherapeutics, Inc.

• 

  FDA Review: Incyte, Pfizer, Iovance and More

  8/26/2022

  The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.

• Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

  8/25/2022

  Iovance Biotherapeutics, Inc. today announced that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for lifileucel.

• Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates

  8/4/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported second quarter and first half 2022 financial results and corporate updates.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 22, 2022

  7/22/2022

  Iovance Biotherapeutics, Inc. announced that on July 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 39,400 shares of Iovance’s common stock to 15 new non-executive employees.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 17, 2022

  6/17/2022

  Iovance Biotherapeutics, Inc. announced that on June 16, 2022, the Company approved the grant of inducement stock options covering an aggregate of 68,225 shares of Iovance’s common stock to 14 new non-executive employees.

• Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

  6/13/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the company’s Board of Directors, effective June 10, 2022.

• Iovance Biotherapeutics to Present at Upcoming Conferences in June 2022

  6/8/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in June.

• Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

  5/26/2022

  Iovance Biotherapeutics, Inc. reported clinical results from its C-144-01 clinical study in patients with advanced melanoma who progressed on prior anti-PD-1/L1 therapy, and if BRAF mutation positive, also on prior BRAF or BRAF/MEK inhibitor therapy.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 20, 2022

  5/20/2022

  Iovance Biotherapeutics, Inc. announced that on May 19, 2022, the Company approved the grant of inducement stock options covering an aggregate of 146,700 shares of Iovance’s common stock to 17 new non-executive employees.

• Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates

  5/5/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported first quarter 2022 financial results and corporate updates.

• Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting

  4/27/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanoma will be highlighted at the upcoming 2022 ASCO Annual Meeting.

• Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022

  4/26/2022

  Iovance Biotherapeutics, Inc. will report its first quarter financial results on Thursday, May 5, 2022.

• Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

  4/25/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Apr 22, 2022

  4/22/2022

  Iovance Biotherapeutics, Inc. announced that on April 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 323,675 shares of Iovance’s common stock to 34 new non-executive employees.

• Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

  4/5/2022

  Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has provided feedback on April 1, 2022 regarding Iovance’s proposed matrix of potency assays for its upcoming Biologics License Application for lifileucel in metastatic melanoma.

• Iovance Biotherapeutics to Present at Upcoming Conferences - Mar 16, 2022

  3/16/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in March.

• Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)

  3/15/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Mar 15, 2022

  3/15/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on March 14, 2022, the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 667,725 shares of Iovance’s common stock to nineteen new non-executive employees.

• Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

  3/8/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting.

• Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

  2/24/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported fourth quarter and full year 2021 financial results and corporate updates.